Fig. 9.

Western blot analysis showing significant (*P < 0.05) decreases in levels of phosphorylated (Thr³⁸) PKC-potentiated inhibitor (CPI-17; A) and phosphorylated (Thr¹⁸/Ser¹⁹) 20-kDa myosin regulatory light chain (MLC₂₀; C; *P < 0.05), but not phosphorylated (Thr⁶⁹⁶) myosin phosphatase-targeting subunit 1 (MYPT1; B; P > 0.05), in RSM following pretreatment with calphostin C and Gö-6850 (10⁻⁵ M). Y-27632 causes a significant decrease in levels of phosphorylated (Thr³⁸) CPI-17 and phosphorylated (Thr¹⁸/Ser¹⁹) MLC₂₀, as well as phosphorylated (Thr⁶⁹⁶) MYPT1 (A–C; *P < 0.05).